Zevia PBC heads into Thursday's post-close session on an unusual footing: the company just delivered a Q1 sales beat and raised full-year guidance, yet the stock dropped 5% on Tuesday to $1.25 — making the reaction to Wednesday's numbers the immediate thing to watch.
The earnings print itself was strong by recent standards. Q1 revenue of $46.1M cleared the consensus estimate of $41.0M by more than 12%. Zevia lifted its FY2026 sales guidance to a $170M–$175M range, edging above the $170.8M estimate at the midpoint. Q2 guidance of $43M–$45M came in a touch light against the $45.6M consensus — and that gap is likely what drove Tuesday's selloff. Prior earnings reactions have been modest: the February 2026 print produced a one-day move of -10%, while the Q4 release in late February 2026 recovered 3% on the day and held those gains over the following week. The setup this time is a stock already trading near multi-year lows at $1.25, with guidance that barely missed on the Q2 line but beat on the full year.
Positioning tells a relaxed story, at least from the shorts. Short interest has fallen sharply — down more than 34% over the past month to roughly 2.7% of the free float — suggesting bears have been covering, not adding. Borrowing costs are negligible at 0.44% annualised, and availability in the lending market is ample, meaning there is no meaningful squeeze pressure from this angle. Options traders look more bullish than usual. The put/call ratio is running at just 0.32, well below its 20-day average of 0.94 and close to the low end of its one-year range. That's a notably call-heavy lean for a micro-cap heading into results.
The Street remains positive but thinly covered. Telsey Advisory Group holds an Outperform rating with a $5.00 target — though that was trimmed from $6.00 in February after the last earnings miss. Morgan Stanley is more cautious, maintaining Equal-Weight with a target last set at $2.70 in August 2025. With the stock at $1.25, both targets sit well above the current price, implying significant upside on paper; however, given the stock's consistent drift lower since mid-2025, those targets likely overstate where the Street would price risk today. The mean analyst target of $4.18 is notable but should be read cautiously in that context. The bull case centres on Zevia's Costco and Walmart distribution gains, refreshed branding, and improving EBITDA margins. Bears point to commodity cost volatility, the risk of further promotional pullback, and the fragility of the consumer goods demand backdrop.
Institutional ownership gives one more data point worth flagging. Topline Capital Management initiated a position of nearly 6 million shares — 8.3% of the company — as reported in February 2026, making it a new and sizeable holder. BlackRock and Vanguard both added modestly through March. Against that, insiders have been consistent sellers: CEO Amy Taylor sold shares across three transactions in late March at prices around $1.14–$1.17, and CFO Girish Satya also sold in late March. The 90-day insider net is a positive figure at the aggregate level only because of earlier period offsetting; the recent directional read from C-suite trades is clearly one of distribution rather than accumulation.
The Q2 guidance miss is the friction point to monitor when the market opens Thursday. A stock at $1.25 with a fresh top-line beat and raised annual guidance, but a Q2 guide below consensus, now faces the question of whether the call-heavy options market was right to lean positive — or whether the CEO's March selling was the more telling signal.
See the live data behind this article on ORTEX.
Open ZVIA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
